Lixisenatide Gains Evidence Of A Weight Loss Benefit
This article was originally published in The Pink Sheet Daily
Sanofi/Zealand's GLP-1 agonist lixisenatide continues to show promise in the latest GetGoal results, this time in type 2 diabetics inadequately controlled on sulfonylureas.
You may also be interested in...
Once-a-day here to stay? With once-weekly taspoglutide just officially rejected by Roche and long-lasting Bydureon delayed on safety, Zealand CEO talks up the virtues of QD GLP-1 analogs.
Victoza and its modern insulins franchise drive 2010 revenues growth at Danish diabetes specialist Novo Nordisk.
During business update, French pharma outlines market of 9 million potential patients for the drug combo.